RU94046463A - Антиандрогенное соединение, предшественник лекарственного средства, фармацевтические композиции, способ лечения или предотвращения заболеваний - Google Patents

Антиандрогенное соединение, предшественник лекарственного средства, фармацевтические композиции, способ лечения или предотвращения заболеваний

Info

Publication number
RU94046463A
RU94046463A RU94046463/04A RU94046463A RU94046463A RU 94046463 A RU94046463 A RU 94046463A RU 94046463/04 A RU94046463/04 A RU 94046463/04A RU 94046463 A RU94046463 A RU 94046463A RU 94046463 A RU94046463 A RU 94046463A
Authority
RU
Russia
Prior art keywords
diseases
medical treatment
prevention
pharmaceutical compositions
drug precursor
Prior art date
Application number
RU94046463/04A
Other languages
English (en)
Other versions
RU2141966C1 (ru
Inventor
Лабри Фернанд
Ca]
Меранд Ив
М. Сингх Шанкар
Original Assignee
Андорешерш
Андорешерш, Инк.
Инк. (CA)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Андорешерш, Андорешерш, Инк., Инк. (CA) filed Critical Андорешерш
Publication of RU94046463A publication Critical patent/RU94046463A/ru
Application granted granted Critical
Publication of RU2141966C1 publication Critical patent/RU2141966C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/0037—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0044—Alkenyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Предлагаются производные, имеющие андрогенное ядро и содержащие специфические заместители в положении 17 альфа, для использования в качестве антиандрогенов для лечения андрогензависимых заболеваний. В некоторых предпочтительных вариантах осуществления изобретения соединение, EM-250смешивают в композицию вместе с фармацевтически приемлемым разбавителем или носителем для местного использования при лечении андрогензависимых заболеваний кожи.

Claims (1)

  1. Предлагаются производные, имеющие андрогенное ядро и содержащие специфические заместители в положении 17 альфа, для использования в качестве антиандрогенов для лечения андрогензависимых заболеваний. В некоторых предпочтительных вариантах осуществления изобретения соединение
    Figure 00000001
    , EM-250
    смешивают в композицию вместе с фармацевтически приемлемым разбавителем или носителем для местного использования при лечении андрогензависимых заболеваний кожи.
RU94046463A 1993-05-17 1993-05-20 Антиандрогенные соединения, предшественник антиандрогенного соединения, фармацевтические композиции RU2141966C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6061293A 1993-05-17 1993-05-17
US08/060,612 1993-05-17
PCT/CA1993/000216 WO1994026767A1 (en) 1993-05-17 1993-05-20 Improved antiandrogens

Publications (2)

Publication Number Publication Date
RU94046463A true RU94046463A (ru) 1997-02-27
RU2141966C1 RU2141966C1 (ru) 1999-11-27

Family

ID=22030624

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94046463A RU2141966C1 (ru) 1993-05-17 1993-05-20 Антиандрогенные соединения, предшественник антиандрогенного соединения, фармацевтические композиции

Country Status (14)

Country Link
EP (1) EP0650495B1 (ru)
JP (1) JP2741286B2 (ru)
KR (1) KR100241228B1 (ru)
AT (1) ATE197458T1 (ru)
CA (1) CA2136303A1 (ru)
CZ (2) CZ285893B6 (ru)
DE (1) DE69329649D1 (ru)
FI (1) FI945458A (ru)
HU (1) HUT69408A (ru)
PL (1) PL307333A1 (ru)
RU (1) RU2141966C1 (ru)
SK (1) SK139194A3 (ru)
TW (1) TW259791B (ru)
WO (1) WO1994026767A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879711A (en) * 1997-11-07 1999-03-09 Sequeira; Joel A. Stable antiandrogenic gel composition
BR9908592A (pt) 1998-03-11 2001-04-24 Endorech Inc Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
WO2002089802A2 (en) 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
EP1423381B1 (en) 2001-09-06 2007-01-03 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
JP4309761B2 (ja) 2001-10-17 2009-08-05 シェーリング コーポレイション アンドロゲン依存性疾患の治療を目的とする１７βヒドロキシステロイドデヒドロゲナーゼ３型の阻害剤としてのピペリジンアセトアミンおよびピペラジンアセトアミン
JP4563032B2 (ja) * 2002-01-15 2010-10-13 メルク・シャープ・エンド・ドーム・コーポレイション アンドロゲン受容体モジュレータとしての１７−ヒドロキシ−４−アザ−アンドロスタン−３−オン
AR042046A1 (es) 2002-11-18 2005-06-08 Schering Corp Inhibidores de 17 beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades que dependen de androgenos
MXPA05006485A (es) 2002-12-17 2005-08-26 Schering Corp Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgeno.
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1081494A (en) * 1965-09-14 1967-08-31 British Drug Houses Ltd 17ª‡-(alka-1',3'-diynyl)-steroids
US3875188A (en) * 1968-04-10 1975-04-01 Eugene E Galantay 17-Beta-alpha-lower alkyl allene-substituted steroids
JPS5513273A (en) * 1978-07-13 1980-01-30 Kanebo Ltd Readily absorbable thiazolidine prodrug of anti- inflammatory corticosteroid and its drug composition
FR2430952A1 (fr) * 1978-07-13 1980-02-08 Roussel Uclaf Nouveaux derives acetyleniques de l'androst 4-ene, leur procede de preparation et leur application comme medicament
JP2959839B2 (ja) * 1989-07-07 1999-10-06 アンドルシェルシュ・インコーポレイテッド 性ステロイド活性の抑制における使用のためのアンドロゲン誘導体

Also Published As

Publication number Publication date
EP0650495B1 (en) 2000-11-08
CZ285893B6 (cs) 1999-11-17
HUT69408A (en) 1995-09-28
RU2141966C1 (ru) 1999-11-27
DE69329649D1 (de) 2000-12-14
JP2741286B2 (ja) 1998-04-15
CZ287991B6 (cs) 2001-03-14
SK139194A3 (en) 1995-07-11
WO1994026767A1 (en) 1994-11-24
EP0650495A1 (en) 1995-05-03
JPH08510988A (ja) 1996-11-19
TW259791B (ru) 1995-10-11
FI945458A0 (fi) 1994-11-21
ATE197458T1 (de) 2000-11-11
KR100241228B1 (ko) 2000-02-01
FI945458A (fi) 1995-01-16
CA2136303A1 (en) 1994-11-24
CZ282494A3 (en) 1995-12-13
PL307333A1 (en) 1995-05-15

Similar Documents

Publication Publication Date Title
AP1422A (en) 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent.
HUP9902121A2 (hu) Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
GEP20053595B (en) Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment
RU95107892A (ru) Производные 11,21-бисфенил-19-норпрегнана, способ их получения, фармацевтическая композиция на их основе и способ ее получения
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
RU94046463A (ru) Антиандрогенное соединение, предшественник лекарственного средства, фармацевтические композиции, способ лечения или предотвращения заболеваний
US5985924A (en) Metastasis suppressory agents
FR2850023B1 (fr) Medicaments pour le systeme nerveux
RU95110937A (ru) Хинолоновые и акридиноновые соединения, способ их получения, фармацевтическая композиция и промежуточные соединения
RU2001101892A (ru) Производное тестостерона
UA42733C2 (ru) Производные биснафталимида и их фармацевтически приемлемые кислотно-аддитивные соли, фармацевтическая композиция с цитотоксической активностью, которая их содержит
FR2081436B1 (ru)
KR970704436A (ko) 항종양제로서 유용한 테르페노이딕 유도체 (사르코딕타인) (terpenoidic derivatives (sarcodictyins) useful as antitumor agents)
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
EA200600377A1 (ru) Новая композиция
SE9901572D0 (sv) New compounds
CA2256391A1 (en) Anticoagulant peptidyl-arginine aldehyde derivatives
KR960700701A (ko) 파라세타몰 및 l-시스테인 또는 이것의 전구물질을 함유하는 약제조성물(pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof)
GEP20043225B (en) 1-Trifluoromethyl-4-Hydroxy-7- Piperidinyl-Aminomethylchroman Derivatives
FR2614890B1 (fr) Compose resultant du couplage d'une molecule a structure chimiosensibilisante et d'une molecule a structure cytotoxique, procede de preparation, application a titre de medicament et compositions pharmaceutiques le contenant
US3129137A (en) Method of inhibiting gastro-intestinal irritation
WO2001007029A3 (en) Substituted guanidines and the use thereof
KR910006270A (ko) 약리적 활성 화합물 제법 및 용도
KR940002268A (ko) 21-클로로-프레그난 유도체